Gastric and oesophageal cancer trials in Austria

7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.

• Phase 1/2Taking people
  EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

  Where

  Linz

  Age

  18 years and over

  People

  160 worldwide

  Run by

  Eikon Therapeutics

  See details and how to joinNCT07262619 · EU 2026-525248-13-00
• Phase 3Taking people
  A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

  Where

  Linz, Salzburg, Vienna, Wiener Neustadt

  Age

  18 years and over

  People

  840 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT06764875 · EU 2024-512583-57-00
• Phase 3Withdrawn
  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  Where

  Linz, Rankweil, Vienna, Wiener Neustadt

  Age

  18 years and over

  People

  2,130 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT07431281 · EU 2024-519787-40-00
• Phase 3Taking people
  A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  Where

  Linz, Vienna

  Age

  18 years and over

  People

  351 worldwide

  Run by

  BeOne Medicines

  See details and how to joinNCT07043400 · EU 2025-522862-58-00
• Phase 3Taking people
  Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer

  Where

  Graz, Innsbruck, Vienna, Wiener Neustadt

  Age

  18 years and over

  People

  228 worldwide

  Run by

  Daiichi Sankyo Inc.

  See details and how to join2024-513122-27-00
• Phase 3Taking people
  Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  Where

  Graz, Innsbruck, Vienna, Wiener Neustadt

  Age

  18 years and over

  People

  726 worldwide

  Run by

  Daiichi Sankyo

  See details and how to joinNCT06731478
• No phaseNot yet taking people in Austria
  Digitally Supported Prehabilitation Before Major Visceral Cancer Surgery

  Where

  Saint Veit Im Pongau, Salzburg

  Age

  18 years and over

  People

  30

  Run by

  Ludwig Boltzmann Institute for Digital Health and Prevention

  See details and how to joinNCT07658313